HC Wainwright Reiterates Buy Rating on COAG
HC Wainwright maintains its buy rating on COAG with a $40 price target, a 56.80% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on COAG with a $40 price target on June 17, 2026.
- COAG shares traded around $25.51, highlighting analyst optimism with a significant upside potential.
- Other firms like Wedbush and Jefferies also have buy ratings on COAG, with targets ranging from $36 to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, HC Wainwright reiterated its buy rating for COAG, setting a price target of $40. This reflects continued confidence in the company's prospects.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on COAG with a $40 price target on June 17, 2026. This follows similar actions from other analysts. On May 26, 2026, Wedbush initiated coverage with a buy rating and a $42 target, while Jefferies also initiated with a buy rating and a $39 target. Evercore ISI Group set the highest target at $50, and Goldman Sachs initiated with a buy rating and a $36 target.
Hemab Therapeutics Holdings, Inc. Stock Down 43.1%
Shares of COAG traded near $25.51, indicating that analysts see a significant upside potential. With multiple buy ratings and varied price targets, the stock is attracting attention from investors interested in its growth potential.
Bottom Line
HC Wainwright's reiterated buy rating and $40 target for COAG suggest confidence in the company's future. Investors often track such analyst updates for insights into potential stock movements. It's important to remember that these ratings reflect the analysts' views as of the report date and are subject to change.
Get Hemab Therapeutics Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $COAG, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.